METOPRINE, AN INHIBITOR OF HISTAMINE N-METHYLTRANSFERASE BUT NOT CATECHOL-O-METHYLTRANSFERASE, SUPPRESSES FEEDING IN SATED AND IN FOOD-DEPRIVED RATS

被引:0
|
作者
LECKLIN, A
TUOMISTO, L
MACDONALD, E
机构
关键词
FOOD INTAKE; CATECHOL-O-METHYLTRANSFERASE; HISTAMINE; HISTAMINE-N-METHYLTRANSFERASE; METOPRINE;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Metoprine is a histamine N-methyltransferase (HMT) inhibitor often used to elevate endogenous histamine (HA) levels when studying the role of brain HA. Since central histaminergic systems may be involved in the regulation of feeding, the effect of metoprine on food intake was studied in sated and in food deprived rats. The treatment caused a dose-dependent decrease in food intake in sated rats. It also suppressed deprivation-induced-feeding. To clarify the specificity of the treatment, the effect of metoprine on another methylating enzyme, catechol-O-methyltransferase (COMT), was examined indirectly by examining the ratio of the non-methylated dopamine metabolite, dihydroxyphenylacetic acid (DOPAC) to that of its methylated product homovanillic acid(HVA). The dopamine metabolites did not change in a manner consistent with COMT inhibition, but instead a transient decrease in DOPAC levels was observed. However, the suppression of feeding is considered to be related to the metoprine-induced inhibition of brain HA catabolism and not with the changes in dopaminergic systems. Metoprine had no effect on brain concentration of serotonin (5-HT) or its metabolite 5-hydroxyindo-leacetic acid (5-HIAA). The results provide further support for the role of brain HA in the control of feeding behavior.
引用
收藏
页码:47 / 52
页数:6
相关论文
共 50 条
  • [1] Inhibitory effects of the histamine N-methyltransferase inhibitor metoprine on methamphetamine actions
    Kitanaka, Junichi
    Kitanaka, Nobue
    Sakamoto, Tomoyuki
    Okumura, Satoshi
    Tanaka, Koh-ichi
    Nishiyama, Nobuyoshi
    Takemura, Motohiko
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2016, 130 (03) : S222 - S222
  • [2] Methylation pharmacogenetics: Catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase
    Weinshilboum, RM
    Otterness, DM
    Szumlanski, CL
    ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1999, 39 : 19 - 52
  • [3] DISTRIBUTION OF CATECHOL-O-METHYLTRANSFERASE, HISTAMINE N-METHYLTRANSFERASE AND MONOAMINE-OXIDASE IN SPECIFIC AREAS OF RAT-BRAIN
    SAAVEDRA, JM
    BROWNSTEIN, MJ
    PALKOVITS, M
    BRAIN RESEARCH, 1976, 118 (01) : 152 - 156
  • [4] Cardiac and regional haemodynamic effects of histamine N-methyltransferase inhibitor metoprine in haemorrhage-shocked rats
    Jochem, J
    INFLAMMATION RESEARCH, 2004, 53 (07) : 316 - 323
  • [5] Cardiac and regional haemodynamic effects of histamine N-methyltransferase inhibitor metoprine in haemorrhage-shocked rats
    J. Jochem
    Inflammation Research, 2004, 53 : 316 - 323
  • [6] Amitriptyline, amodiaquine and metoprine interactions with rat kidney histamine N-methyltransferase
    Rajtar, S.
    Irman-Florjanc, T.
    FEBS JOURNAL, 2006, 273 : 283 - 284
  • [7] Chronopharmacology of nebicapone, a new catechol-O-methyltransferase inhibitor
    Almeida, Luis
    Loureiro, Ana I.
    Vaz-da-Silva, Manuel
    Torrao, Leonel
    Maia, Joana
    Fernandes-Lopes, Carlos
    Falcao, Amilcar
    Igreja, Bruno
    Wright, Lyndon
    Soares-da-Silva, Patricio
    CURRENT MEDICAL RESEARCH AND OPINION, 2010, 26 (05) : 1097 - 1108
  • [8] CATECHOL-O-METHYLTRANSFERASE, HISTAMINE-N-METHYLTRANSFERASE AND METHANOL FORMING ENZYME IN RAT PINEAL-GLAND
    BACKSTROM, M
    WETTERBERG, L
    LIFE SCIENCE PART 1 PHYSIOLOGY & PHARMACOLOGY, 1972, 11 (06): : 293 - +
  • [9] Salvianolic acid B as a substrate and weak catechol-O-methyltransferase inhibitor in rats
    Qi, Qu
    Cao, Lijuan
    Li, Feiyan
    Wang, Hong
    Liu, Huiying
    Hao, Haiping
    Hao, Kun
    XENOBIOTICA, 2015, 45 (09) : 820 - 827
  • [10] IDENTIFICATION OF MAJOR METABOLITES OF THE CATECHOL-O-METHYLTRANSFERASE INHIBITOR ENTACAPONE IN RATS AND HUMANS
    WIKBERG, T
    VUORELA, A
    OTTOILA, P
    TASKINEN, J
    DRUG METABOLISM AND DISPOSITION, 1993, 21 (01) : 81 - 92